Exploring the sounds of silence: RNAi-mediated gene silencing for target identification and validation.

Abstract excerpt

Drug development begins with the identification and early preclinical validation of novel biological targets, a process often called 'target identification and validation'. This process usually uses various approaches, such as observations from literature and findings from animal or clinical studies, together with cutting edge molecular techniques that include analyses of gene and protein expression, interaction...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Drug Design
• Share to Drug Evaluation, Preclinical
• Share to Gene Library